News
In Q2 2025, West Pharmaceutical's revenues increased by 9.17%, suggesting that the destocking effect is vanishing. Read why ...
West Pharmaceutical Services, Inc.'s Q2 results highlight growth driven by GLP-1 drugs and high-value products. Click for WST ...
Analysts say the departure of the CBER head may alleviate overhang in the cell and gene therapy space. Vinay Prasad, head of the Center for Biologics Evaluation and Research (CBER) at the US Food and ...
2d
24/7 Wall St. on MSN4 High-Yield Blue-Chip Pharmaceutical Giants Offer Huge Total Return Potential
Here are four high-yield blue-chip pharmaceutical stocks positioned to outperform and offer huge total return potential.
Eramol, a UK-based pharmaceutical contract development and manufacturing organisation (CDMO), is pleased to announce ...
Boster Bio pioneers free antibody validation, revolutionizing IHC services with guaranteed reagent reliability, setting new ...
While a one-stop shop still has its advantages, sponsor companies and CDMOs are starting to see each other not as ...
6d
Vietnam Investment Review on MSNPharma sector faces up to AI hurdles
While AI and innovation are generating increasing spillover effects in the global pharmaceutical industry and improving ...
NetraMark Holdings Inc. (the 'Company” or 'NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company transforming clinical trials and Pentara Corporation ( ...
The American Medical Association expresses "deep concern" over a report that Health and Human Services Secretary Robert F.
By end users, in 2024, the pharmaceutical companies segment accounted for the largest market share of the healthcare analytical testing services market. This significant market presence, driven by the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results